To hear about similar clinical trials, please enter your email below

Trial Title: Low-field MRI for Breast Cancer Screening

NCT ID: NCT05486520

Condition: Breast Benign
Malignant Neoplasm of Breast
Breast Malignant Tumor

Conditions: Official terms:
Neoplasms
Breast Neoplasms

Conditions: Keywords:
Breast pathologies benign
Breast pathologies malignant

Study type: Interventional

Study phase: N/A

Overall status: Enrolling by invitation

Study design:

Allocation: Non-Randomized

Intervention model: Parallel Assignment

Primary purpose: Diagnostic

Masking: None (Open Label)

Intervention:

Intervention type: Device
Intervention name: Magnetic Resonance Imaging (MRI)
Description: MR images will be acquired using an ultra-low magnetic field 6.5 mT scanner located at the Martinos Center. The study time is estimated to be a maximum of 90 minutes with a maximum of 60 minutes of imaging time
Arm group label: BREAST MRI IMAGES FROM HEALTHY VOLUNTEERS
Arm group label: BREAST MRI IMAGES FROM PERSONS WITH KNOWN BREAST PATHOLOGIES BENIGN AND MALIGNANT

Summary: This research study wants to learn more about improving the attainable image quality for ultra-low field MRI of the breast using new data acquisition methods(also called MRI pulse sequences) and image reconstruction algorithms. For this pilot study, are testing a new method to image breast cancers at ultra-low magnetic field. The findings from this breast imaging technique will be compared with results obtained from standard mammograms, ultrasounds, MRIs, clinical examinations, and pathology evaluations, when available. The ultra-low field breast MRI performed for this study will be for research purposes and will not be used to guide clinical care.

Detailed description: This research study is a Feasibility Study, which is the first-time investigators are examining the use of ultra-low field MRI to image breast cancer. The purpose of the study is to develop, test and improve new software techniques for our magnetic resonance imaging (MRI) systems. In developing new, ultra-low field MRI scanners develop sequences and other software algorithms from time to time. This study will enroll both healthy participants and persons with breast cancer. This investigation will also compare these images to standard mammograms, ultrasounds, MRIs, clinical examinations, and pathology evaluations when available. It is expected that about 40 people will take part in this research study.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Informed consent will be obtained from the adult volunteer subjects by the principal investigator, the coinvestigators, or the study staff prior to the imaging session. The investigator obtaining consent will explain in detail the protocol of the study, its purpose, and potential benefits to the society. - Subjects will be informed about the minimal risks of ultra-low magnetic fields) and of low-frequency nonionizing RF radiation involved in ultra-low field MR imaging. Subjects will also be informed about small space within the magnet. Unlike high-field scanners, there is essentially no sound produced by the imaging gradients, so hearing protection is not required. - Subjects will be informed that if they feel uncomfortable with the study, they can choose to terminate the study at any time. They will be informed that their refusal to participate in the study or choosing to terminate it at some point will have no effect on care and treatment received by them at MGH now or in future. - The subjects will be informed that their personal information will be protected as per the HIPAA guidelines. - The subjects will have at least 15 minutes to consider participation. - Subjects will undergo MR contraindication screening to ensure that they meet the basic inclusion/exclusion criteria for the study and give written informed consent immediately prior to the MR imaging study. - Recruit adult female volunteers of any race or ethnic background, between the ages of 20 to 80, who are either scheduled for breast imaging and/or a percutaneous biopsy. - All efforts will be taken to find interpreters for volunteers who do not understand English, enabling them to be screened and consented with the short-form consent form so that they may participate in this study. Exclusion Criteria: - Exclusion criteria include MR contraindications - Electronic implants such as cardiac pacemakers or perfusion pumps - Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants - Ferromagnetic objects such as jewelry or metal clips in clothing - Pregnant or breast feeding women - A history of uncontrolled seizures - Claustrophobia - Any greater than normal potential for cardiac arrest - Subjects less than 18 years of age or over 80 years of age.

Gender: Female

Minimum age: 20 Years

Maximum age: 80 Years

Healthy volunteers: Accepts Healthy Volunteers

Locations:

Facility:
Name: Massachusetts General Hospital

Address:
City: Boston
Zip: 02115
Country: United States

Start date: September 1, 2022

Completion date: September 1, 2024

Lead sponsor:
Agency: Massachusetts General Hospital
Agency class: Other

Collaborator:
Agency: National Institutes of Health (NIH)
Agency class: NIH

Source: Massachusetts General Hospital

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05486520

Login to your account

Did you forget your password?